Genelux Corporation (NASDAQ:GNLX – Get Free Report) CEO Thomas Zindrick sold 34,463 shares of Genelux stock in a transaction on Monday, August 31st. The stock was sold at an average price of $2.67, for a total transaction of $92,016.21. Following the completion of the transaction, the chief executive officer directly owned 1,226,427 shares in the company, valued at $3,274,560.09. This represents a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Thomas Zindrick also recently made the following trade(s):
- On Tuesday, August 4th, Thomas Zindrick sold 3,023 shares of Genelux stock. The shares were sold at an average price of $2.95, for a total value of $8,917.85.
Genelux Trading Down 1.9%
Shares of GNLX opened at $2.55 on Thursday. The firm has a market cap of $115.37 million, a PE ratio of -2.97 and a beta of 0.57. Genelux Corporation has a 12 month low of $2.29 and a 12 month high of $8.53. The stock has a fifty day moving average price of $2.83 and a 200-day moving average price of $2.78.
Hedge Funds Weigh In On Genelux
Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Genelux in the 2nd quarter worth $1,323,000. Geode Capital Management LLC grew its stake in Genelux by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 381,407 shares of the company’s stock valued at $1,664,000 after purchasing an additional 27,567 shares during the last quarter. Bank of America Corp DE purchased a new stake in Genelux during the 2nd quarter valued at about $990,000. Flputnam Investment Management Co. acquired a new position in shares of Genelux in the second quarter valued at about $697,000. Finally, Global Retirement Partners LLC acquired a new position in shares of Genelux in the second quarter valued at about $686,000. 37.33% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on the company. Wall Street Zen upgraded Genelux from a “strong sell” rating to a “sell” rating in a research note on Sunday, August 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research report on Friday, July 17th. Finally, Benchmark reiterated a “speculative buy” rating on shares of Genelux in a research note on Tuesday, August 18th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.
Check Out Our Latest Stock Analysis on GNLX
About Genelux
Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.
Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.
Featured Stories
- Five stocks we like better than Genelux
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
